» Articles » PMID: 20853176

A 10-year Follow-up of Treatment Outcomes in Patients with Early Stage Breast Cancer and Clinically Negative Axillary Nodes Treated with Tangential Breast Irradiation Following Sentinel Lymph Node Dissection or Axillary Clearance

Overview
Specialty Oncology
Date 2010 Sep 21
PMID 20853176
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

We compare long-term outcomes in patients with node negative early stage breast cancer treated with breast radiotherapy (RT) without the axillary RT field after sentinel lymph node dissection (SLND) or axillary lymph node dissection (ALND). We hypothesize that though tangential RT was delivered to the breast tissue, it at least partially sterilized occult axillary nodal metastases thus providing low nodal failure rates. Between 1995 and 2001, 265 patients with AJCC stages I-II breast cancer were treated with lumpectomy and either SLND (cohort SLND) or SLND and ALND (cohort ALND). Median follow-up was 9.9 years (range 8.3-15.3 years). RT was administered to the whole breast to the median dose of 48.2 Gy (range 46.0-50.4 Gy) plus boost without axillary RT. Chi-square tests were employed in comparing outcomes of two groups for axillary and supraclavicular failure rates, ipsilateral in-breast tumor recurrence (IBTR), distant metastases (DM), and chronic complications. Progression-free survival (PFS) was compared using log-rank test. There were 136/265 (51%) and 129/265 (49%) patients in the SLND and ALND cohorts, respectively. The median number of axillary lymph nodes assessed was 2 (range 1-5) in cohort SLND and 18 (range 7-36) in cohort ALND (P < 0.0001). Incidence of AFR and SFR in both cohorts was 0%. The rates of IBTR and DM in both cohorts were not significantly different. Median PFS in the SLND cohort is 14.6 years and 10-year PFS is 88.2%. Median PFS in the ALND group is 15.0 years and 10-year PFS is 85.7%. At a 10-year follow-up chronic lymphedema occurred in 5/108 (4.6%) and 40/115 (34.8%) in cohorts SLND and ALND, respectively (P = 0.0001). This study provides mature evidence that patients with negative nodes, treated with tangential breast RT and SLND alone, experience low AFR or SFR. Our findings, while awaiting mature long-term data from NSABP B-32, support that in patients with negative axillary nodal status such treatment provides excellent long-term cure rates while avoiding morbidities associated with ALND or addition of axillary RT field.

Citing Articles

The prevalence and risk factors for physical impairments in Chinese post-cancer treated breast cancer survivors: a 4 years' cross-sectional study at a single center.

Chen D, Li L, Jiang L, Jia J Sci Rep. 2023; 13(1):18458.

PMID: 37891422 PMC: 10611789. DOI: 10.1038/s41598-023-45731-x.


Breast Cancer-Related Lymphedema (BCRL) and Bioimpedance Spectroscopy: Long-Term Follow-Up, Surveillance Recommendations, and Multidisciplinary Risk Factors.

Jeffers E, Wagner J, Korentager S, Larson K, Balanoff C, Baker J Ann Surg Oncol. 2023; 30(10):6258-6265.

PMID: 37535267 DOI: 10.1245/s10434-023-13956-9.


Quantifying radiation in the axillary bed at the site of lymphedema surgical prevention.

Friedman R, Spiegel D, Kinney J, Willcox J, Recht A, Singhal D Breast Cancer Res Treat. 2023; 201(2):299-305.

PMID: 37382815 DOI: 10.1007/s10549-023-06988-y.


Breast-conserving therapy versus mastectomy for breast cancer: a ten-year follow-up single-center real-world study.

Li W, Zheng Y, Wu H, Li X Gland Surg. 2022; 11(7):1148-1165.

PMID: 35935564 PMC: 9346212. DOI: 10.21037/gs-22-142.


A randomized study to prevent lymphedema in women treated for breast cancer: CALGB 70305 (Alliance).

Paskett E, Le-Rademacher J, Oliveri J, Liu H, Seisler D, Sloan J Cancer. 2020; 127(2):291-299.

PMID: 33079411 PMC: 7790907. DOI: 10.1002/cncr.33183.


References
1.
Olivier J, Verhaeghe J, Butarelli M, Marchal F, Houvenaeghel G . [Functional anatomy of the lymphatic drainage of the breast: contribution of sentinel lymph node biopsy]. Ann Chir. 2006; 131(10):608-15. DOI: 10.1016/j.anchir.2006.06.011. View

2.
Mansel R, Fallowfield L, Kissin M, Goyal A, Newcombe R, Dixon J . Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 2006; 98(9):599-609. DOI: 10.1093/jnci/djj158. View

3.
Land S, Kopec J, Julian T, Brown A, Anderson S, Krag D . Patient-reported outcomes in sentinel node-negative adjuvant breast cancer patients receiving sentinel-node biopsy or axillary dissection: National Surgical Adjuvant Breast and Bowel Project phase III protocol B-32. J Clin Oncol. 2010; 28(25):3929-36. PMC: 2940391. DOI: 10.1200/JCO.2010.28.2491. View

4.
Wong J, Recht A, Beard C, Busse P, Cady B, Chaffey J . Treatment outcome after tangential radiation therapy without axillary dissection in patients with early-stage breast cancer and clinically negative axillary nodes. Int J Radiat Oncol Biol Phys. 1997; 39(4):915-20. DOI: 10.1016/s0360-3016(97)00456-2. View

5.
Schlembach P, Buchholz T, Ross M, Kirsner S, Salas G, Strom E . Relationship of sentinel and axillary level I-II lymph nodes to tangential fields used in breast irradiation. Int J Radiat Oncol Biol Phys. 2001; 51(3):671-8. DOI: 10.1016/s0360-3016(01)01684-4. View